MRK — Merck & Co., Inc.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 310158 ·
Last close
$132.92
Market Cap
$327.94B
52W High
$135.05
52W Low
$110.15
ADV30
8,679,599
Next earnings
2026-10-29
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | 16,286,000,000 | 12,091,000,000 | -3,201,000,000 | -4,240,000,000 | 128,685,000,000 | 5,327,000,000 | 82,754,000,000 |
| Dec 2025 | 16,400,000,000 | 10,849,000,000 | 4,065,000,000 | 2,963,000,000 | 136,866,000,000 | 14,565,000,000 | 84,204,000,000 |
| Sep 2025 | 17,276,000,000 | 13,421,000,000 | 6,554,000,000 | 5,785,000,000 | 129,546,000,000 | 18,169,000,000 | 77,639,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$17,890,000,000
Investing CF
$-22,464,000,000
Financing CF
$852,000,000
CapEx
$-3,775,000,000
Dividends Paid
$-8,231,000,000
Buybacks
$-4,794,000,000
EPS Diluted TTM
$1.25
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$66,721,000,000
Inventory
$6,479,000,000
Receivables
$12,210,000,000
ST Investments
$375,000,000
EBIT TTM
$13,152,000,000
Pretax Income TTM
$11,630,000,000
Interest Exp TTM
$1,522,000,000
Analysts
26
Yahoo Snapshot (yfinance, live)
Total Revenue
$66,568,998,912
EBITDA
$28,871,000,064
Free Cash Flow
$15,171,500,032
Enterprise Value
$374,757,457,920
Total Cash
$7,141,000,192
Total Debt
$53,910,999,040
Shares Out
2,467,171,638
Trailing EPS
$1.25
Book Value
$18.58
ROE
7.0%
ROA
11.9%
Div Yield
2.56%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 65,011,000,000 | 22,107,000,000 | 18,254,000,000 | 136,866,000,000 | 84,204,000,000 | — | 16,472,000,000 |
| Dec 2024 | 64,168,000,000 | 20,221,000,000 | 17,117,000,000 | 117,106,000,000 | 70,734,000,000 | — | 21,468,000,000 |
| Dec 2023 | 60,115,000,000 | 2,954,000,000 | 365,000,000 | 106,675,000,000 | 69,040,000,000 | — | 13,006,000,000 |
| Dec 2022 | 59,283,000,000 | 18,282,000,000 | 14,519,000,000 | 109,160,000,000 | 63,102,000,000 | — | 19,095,000,000 |
TTM Snapshot
Revenues TTM
$53,137,000,000
NetIncome TTM
$12,566,000,000
OpCashFlow TTM
$0
Assets (Latest)
$117,106,000,000
Forward EPS
$9.55
Max Pain — expiry 2026-08-21
max pain strike: $125.00 · spot: $135.55 · call oi: 32,293 · put oi: 21,899
Expected Move to 2026-08-21:
±$4.16
(3.07%) —
implied range
$131.40 –
$139.71
· ATM straddle on $136.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NVSEF | NOVARTIS AG | $300.12B | $157.90 | — |
| NVS | NOVARTIS AG | $289.52B | $152.32 | — |
| AZN | ASTRAZENECA PLC | $245.82B | $158.50 | — |
| ABBV | AbbVie Inc. | $439.59B | $248.76 | — |
| ABT | ABBOTT LABORATORIES | $193.18B | $110.91 | — |
News headlines (Yahoo Finance, 1h cache)
Merck (MRK) Stock Fair Value Edges Higher After Analysts Back Pipeline Progress
2026-08-13 20:07 · Yahoo
Merck (MRK) Stock Looks Fully Valued Following Raised Revenue Outlook
2026-08-13 19:11 · Yahoo
The Sharpest Exchanges From ABBV's Earnings Call
2026-08-13 16:10 · Yahoo
Can Keytruda Sustain Merck's Growth in the Second Half of 2026?
2026-08-13 14:00 · Yahoo
This Healthcare Services Stock Has 37% Upside
2026-08-13 12:01 · Yahoo
5 Insightful Analyst Questions From Merck’s Q2 Earnings Call
2026-08-12 23:41 · Yahoo
How ABBV Stock Moved Away From Its Peer Group
2026-08-12 20:49 · Yahoo
Sector Update: Healthcare Stocks Advance Late Afternoon
2026-08-12 19:58 · Yahoo
Amgen Stock And The Price Of A Promise
2026-08-12 19:17 · Yahoo
Is BMY's Growth Portfolio Strong Enough to Offset Legacy Drug Declines?
2026-08-12 18:36 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.